{"id":1654,"date":"2023-06-25T17:29:05","date_gmt":"2023-06-25T17:29:05","guid":{"rendered":"https:\/\/kidneydiseaseclinic.net\/kdc\/atovaquone\/"},"modified":"2023-06-25T19:49:47","modified_gmt":"2023-06-25T19:49:47","slug":"atovaquone","status":"publish","type":"post","link":"https:\/\/kidneydiseaseclinic.net\/kdc\/atovaquone\/","title":{"rendered":"Atovaquone"},"content":{"rendered":"

<\/p>\n

Atovaquone<\/h1>\n

CLINICAL USE<\/h3>\n

Treatment of PCP if intolerant to co-trimoxazole<\/p>\n

DOSE IN NORMAL RENAL FUNCTION<\/h3>\n

750 mg twice daily for 21 days<\/p>\n

PHARMACOKINETICS<\/h3>\n
  • Molecular weight                           :366.8<\/li>\n
  • %Protein binding                           :99.9<\/li>\n
  • %Excreted unchanged in urine     : <1<\/li>\n
  • Volume of distribution (L\/kg)       :0.62 \u00b1 0.19<\/li>\n
  • half-life \u2013 normal\/ESRD (hrs)      :2\u20133 days\/no data
    \n

    DOSE IN RENAL IMPAIRMENT<\/h3>\n

    GFR (mL\/MIN)<\/h4>\n<\/li>\n
  • 20 to 50     : Dose as in normal renal function<\/li>\n
  • 10 to 20     : Dose as in normal renal function<\/li>\n
  • <10           : Dose as in normal renal function. Use with caution
    \n

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES<\/h3>\n<\/li>\n
  • CAPD                :Not dialysed. Dose as in normal renal function<\/li>\n
  • HD                     :Not dialysed. Dose as in normal renal function<\/li>\n
  • HDF\/high flux   :Unknown dialysability. Dose as in normal renal function<\/li>\n
  • CAV\/VVHD      :Unlikely to be dialysed. Dose as in normal renal function
    \n

    IMPORTANT DRUG INTERACTIONS<\/h3>\n

    Potentially hazardous interactions with other drugs<\/li>\n

  • Antibacterials: rifampicin, rifabutin and tetracyclines reduce levels by 50%<\/li>\n
  • Metoclopramide: significant reduction in plasma atovaquone levels
    \n

    ADMINISTRATION<\/h3>\n

    Reconstition<\/h4>\n

    \u2013<\/p>\n

    Route<\/h4>\n

    Oral<\/p>\n

    Rate of Administration<\/h4>\n

    \u2013<\/p>\n

    Comments<\/h4>\n

    \u2013<\/p>\n

    OTHER INFORMATION<\/h4>\n<\/li>\n
  • Administer with food. The presence of food, particularly high fat food, increases bioavailability 2 or 3-fold.<\/li>\n
  • The most commonly reported abnormalities in laboratory parameters are increased liver function tests and amylase levels, and hyponatraemia<\/li>\n","protected":false},"excerpt":{"rendered":"

    Atovaquone CLINICAL USE Treatment of PCP if intolerant to co-trimoxazole<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[7],"class_list":["post-1654","post","type-post","status-publish","format-standard","hentry","category-blog","tag-post-by-auto-php"],"_links":{"self":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/1654","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/comments?post=1654"}],"version-history":[{"count":1,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/1654\/revisions"}],"predecessor-version":[{"id":2887,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/1654\/revisions\/2887"}],"wp:attachment":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/media?parent=1654"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/categories?post=1654"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/tags?post=1654"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}